The GW Ernesto's Pricing Analytics & Health Economics Blog

Home
The GW Ernesto's Pricing Analytics & Health Economics Blog

"Like" to read the latest Pharma Industry News on Pricing and Health Economics. Interested in advert

The Health Economics Journal is the most active Facebook based website for Health Economics, Outcomes Research, Pharmaceuticals Pricing & Reimbursement, and market access resources, news and jobs on the internet. Mission:
The mission of The Health Economics Journal is to be the premier facebook based web site devoted to internet resources focused on health outcomes and health care value. With reso

urces ranging from job opportunities to questionnaires, The Health Economics Journal is a key resource for health outcomes professionals. Description:
The Health Economics Journal was founded in 2011 by Ernesto C. R., Pg.D., Eng., Business Consultant and Pricing/Business Analyst for top pharmaceuticals companies. Continuously updated HealthEconomics.Com contains a world-wide list of resources on outcomes research, health economics, pharmacoeconomics, managed care, value in medicine, health-related quality of life, performance assessment, and quality of care. This easy-to-navigate web site is searchable by publication date and provides visitors the ability to recommend new sites of potential interest and an opportunity for idea exchange. Currently, the website gets more and more visitors every month. ARE YOU INTERESTED IN ADVERTISING IN "THE HEALTH ECONOMICS JOURNAL"? PLEASE SEND A MESSAGE TO OUR INBOX TO RECEIVE PROMOTIONAL DISCOUNTS AND OFFERS ACCORDING TO YOUR ADVERTISER CATEGORY: http://www.facebook.com/messages/thehej

19/12/2023

Los medicamentos que más ingresos han generado en 2023 son los "biológicos", tales como los anticuerpos monoclonales. (Por eso terminan en MAB que significa monoclonal antibody).
Se usan sobre todo enfermedades reumáticas y el manejo del cáncer. Fuente: https://twitter.com/doctormacias/status/1736761965509259349

The drugs that have generated the most revenue in 2023 are "biologics", such as monoclonal antibodies. (That is why they end in "mab", which stands for monoclonal antibody). They are used mainly for rheumatic diseases and cancer management.

Ernesto, experto en Pricing Data Analytics Models en la industria de salud con experiencia en esa área en SUIZA (en la sede central global de la multinacional Novartis Pharmaceuticals Corporation).

Address

Website

http://www.pagevamp.com/page/thehej

Alerts

Be the first to know and let us send you an email when The GW Ernesto's Pricing Analytics & Health Economics Blog posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Business

Send a message to The GW Ernesto's Pricing Analytics & Health Economics Blog:

Shortcuts